ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
Emmessar Biotech & Nutrition informed shareholders without registered email addresses about accessing the Annual Report and 34th AGM Notice via the company's website.
Emmessar Biotech & Nutrition Limited has issued a notice for its 34th Annual General Meeting, scheduled to be held on September 29, 2026, via video conferencing.
Emmessar Biotech & Nutrition Ltd reported revenue from operations of ₹0.1 Cr (+0.0% YoY) and net profit of ₹0.1 Cr (-50.0% YoY) for Q1 FY27.
Emmessar Biotech & Nutrition Limited has scheduled a board meeting for August 07, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.
Emmessar Biotech & Nutrition Ltd reported revenue from operations of ₹0.1 Cr (+0.0% YoY) and net profit of ₹0 Cr for Q4 FY26.
Emmessar Biotech & Nutrition reported a total income of ₹2.41 Crore for FY26. Net profit stood at ₹0.44 Crore, reflecting stable annual performance for investors.
Emmessar Biotech & Nutrition Ltd has scheduled a Board Meeting for May 12, 2026. The meeting will primarily focus on considering and approving the audited financial results for the year ended March 31, 2026. The trading window will remain closed until May 14, 2026.
Emmessar Biotech & Nutrition Ltd has disclosed that it does not meet the criteria for a Large Corporate as of March 31, 2025. The company reported zero outstanding borrowings and holds no credit rating, exempting it from mandatory incremental borrowing requirements under the SEBI framework.